Edition:
United States

Amphastar Pharmaceuticals Inc (AMPH.OQ)

AMPH.OQ on NASDAQ Stock Exchange Global Select Market

18.04USD
16 Aug 2018
Change (% chg)

-- (--)
Prev Close
$18.04
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
85,640
52-wk High
$20.44
52-wk Low
$14.40

Latest Key Developments (Source: Significant Developments)

Amphastar Pharma Receives FDA Approval For Semi-Purified Heparin
Monday, 4 Jun 2018 06:00am EDT 

June 4 (Reuters) - Amphastar Pharmaceuticals Inc ::AMPHASTAR PHARMACEUTICALS RECEIVES FDA APPROVAL FOR SEMI-PURIFIED HEPARIN AT AMPHASTAR NANJING PHARMACEUTICALS.AMPHASTAR PHARMACEUTICALS INC - TO MANUFACTURE HEPARIN SODIUM USP AT CO’S SUBSIDIARY, INTERNATIONAL MEDICATION SYSTEMS LIMITED.  Full Article

Amphastar Pharmaceuticals Reports Q4 Gaap Earnings Per Share $0.03
Monday, 12 Mar 2018 04:05pm EDT 

March 12 (Reuters) - Amphastar Pharmaceuticals Inc ::AMPHASTAR PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR THE THREE MONTHS AND FISCAL YEAR ENDED DECEMBER 31, 2017.Q4 ADJUSTED NON-GAAP EARNINGS PER SHARE $0.38.Q4 GAAP EARNINGS PER SHARE $0.03.Q4 REVENUE $60.4 MILLION VERSUS I/B/E/S VIEW $60.6 MILLION.Q4 EARNINGS PER SHARE VIEW $-0.02 -- THOMSON REUTERS I/B/E/S.  Full Article

Amphastar Pharmaceuticals Reports Q4 GAAP EPS $0.03
Monday, 12 Mar 2018 04:05pm EDT 

March 12 (Reuters) - Amphastar Pharmaceuticals Inc ::AMPHASTAR PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR THE THREE MONTHS AND FISCAL YEAR ENDED DECEMBER 31, 2017.Q4 ADJUSTED NON-GAAP EARNINGS PER SHARE $0.10 .Q4 GAAP EARNINGS PER SHARE $0.03.Q4 REVENUE $60.4 MILLION VERSUS I/B/E/S VIEW $60.6 MILLION.Q4 EARNINGS PER SHARE VIEW $-0.02 -- THOMSON REUTERS I/B/E/S.  Full Article

Amphastar Announces Approval For Sodium Nitroprusside Injection, USP
Tuesday, 19 Dec 2017 06:00am EST 

Dec 19 (Reuters) - Amphastar Pharmaceuticals Inc ::AMPHASTAR ANNOUNCES APPROVAL FOR SODIUM NITROPRUSSIDE INJECTION, USP.AMPHASTAR PHARM - ANTICIPATES LAUNCHING SODIUM NITROPRUSSIDE INJECTION, USP IN Q1 OF 2018.AMPHASTAR PHARMACEUTICALS - FDA GRANTED APPROVAL OF ABBREVIATED NEW DRUG APPLICATION FOR SODIUM NITROPRUSSIDE INJECTION 25MG/ML, 2ML SINGLE DOSE VIAL.  Full Article

Amphastar Announces Approval For Medroxyprogesterone Acetate Injectable Suspension, USP
Wednesday, 29 Nov 2017 02:50pm EST 

Nov 29 (Reuters) - Amphastar Pharmaceuticals Inc ::AMPHASTAR ANNOUNCES APPROVAL FOR MEDROXYPROGESTERONE ACETATE INJECTABLE SUSPENSION, USP.SAYS AMPHASTAR ANTICIPATES LAUNCHING ITS PRODUCT IN Q1 OF 2018.SAYS U.S. FDA GRANTED APPROVAL OF 2 ABBREVIATED NEW DRUG APPLICATIONS FOR MEDROXYPROGESTERONE ACETATE INJECTABLE SUSPENSION.SAYS APPROVAL FOR MEDROXYPROGESTERONE ACETATE INJECTABLE SUSPENSION, USP 150 MG/ML, 1ML VIAL, & 1ML PREFILLED SYRINGE, RESPECTIVELY.  Full Article

Amphastar Pharma reports results for three months ended Sept
Wednesday, 8 Nov 2017 04:05pm EST 

Nov 8 (Reuters) - Amphastar Pharmaceuticals Inc :Amphastar Pharmaceuticals reports financial results for the three months ended September 30, 2017.Q3 GAAP earnings per share $0.00.Q3 revenue $57.9 million versus i/b/e/s view $57.2 million.Q3 adjusted non-GAAP earnings per share $0.07.Q3 earnings per share view $0.02 -- Thomson Reuters I/B/E/S.  Full Article

Amphastar Pharmaceuticals receives FDA approval for sodium bicarbonate injection
Wednesday, 20 Sep 2017 04:22pm EDT 

Sept 20 (Reuters) - Amphastar Pharmaceuticals Inc :Amphastar Pharmaceuticals receives FDA approval for sodium bicarbonate injection.Amphastar Pharmaceuticals Inc - ‍FDA granted approval of co's ANDA for sodium bicarbonate injection 8.4% in 50 ml luer-jet prefilled syringe system​.  Full Article

Amphastar Pharmaceuticals reports Q2 earnings per share $0.04
Wednesday, 9 Aug 2017 04:05pm EDT 

Aug 10 (Reuters) - Amphastar Pharmaceuticals Inc -:Amphastar Pharmaceuticals reports financial results for the three months ended june 30, 2017.Q2 adjusted non-gaap earnings per share $0.11.Q2 gaap earnings per share $0.04.Q2 revenue $65.2 million versus I/B/E/S view $63.3 million.Q2 earnings per share view $0.07 -- Thomson Reuters I/B/E/S.Qtrly net revenues of $65.2 million, a decrease of 4% compared to $68.0 million for three months ended june 30, 2016.Q2 earnings per share view $0.07, revenue view $63.3 million -- Thomson Reuters I/B/E/S.  Full Article

Amphastar announces jury verdict in litigation against Momenta Pharmaceuticals and Sandoz Inc
Monday, 24 Jul 2017 06:00am EDT 

July 24 (Reuters) - Amphastar Pharmaceuticals Inc :Amphastar announces jury verdict in patent litigation against Momenta Pharmaceuticals Inc and Sandoz Inc.Amphastar Pharmaceuticals - ‍jury found claims of Momenta's U.S. patent to be "invalid for lack of enablement and lack of adequate written description"​.  Full Article

Momenta Pharmaceuticals says U.S. court found its patent for manufacturing LOVENOX "was infringed"
Friday, 21 Jul 2017 02:16pm EDT 

July 21 (Reuters) - Momenta Pharmaceuticals Inc ::Momenta Pharmaceuticals announces jury verdict in Enoxaparin Sodium Injection patent litigation against Amphastar.U.S. court issued verdict finding that co's U.S. patent covering methods for manufacturing of generic LOVENOX "was infringed".  Full Article

Amphastar cannot collect $100 mln during Momenta drug patent appeal - judge

A federal judge on Monday ruled that Amphastar Pharmaceuticals Inc must wait to collect a $100 million bond that Momenta Pharmaceuticals Inc and Sandoz Inc posted in a drug patent case it won until after an appellate court hears the dispute.